// App-Quantinova.ai

: Updated results of a phase Ib single-center study of pembrolizumab in combination with chemotherapy in patients with locally advanced or metastatic small cell/neuroendocrine cancers of the prostate and urothelium.

Researchers

Presenter

  • Arnold I. Chin

Principal Investigators

  • Ann Ly

  • Sara Rodriguez

  • Ankush Sachdeva

  • Nazy Zomorodian

  • Hanwei Zhang

  • Jiyoon Kim

  • Gang Li

  • Matthew Rettig

  • Sandy Liu

  • Alexandra Drakaki

Medical Centers

  • UCLA, Los Angeles, CA

  • UCLA David Geffen School of Medicine, Los Angeles, CA

  • Jonsson Comprehensive Cancer Center, UCLA, and VA Greater Los Angeles Healthcare System, Los Angeles, CA

  • Department of Neurology, UCLA, Los Angeles, CA

  • Institute of Urologic Oncology, Los Angeles, CA

  • City of Hope Orange Country Lennar Foundation Cancer Center, Irvine, CA

  • Department of Biostatistics, School of Public Health at the University of California, Los Angeles, Los Angeles, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • Peripheral blood mononuclear cell

  • T-cell receptor

Drug/Treatment

  • Pembrolizumab

  • Carboplatin

  • Docetaxel

  • Etoposide

  • Etoposide phosphate

  • Cisplatin

Outcome

  • N/A

Study Design

  • Cohort

  • Single Center

Phase

  • I

Study Id's

  • NCT03582475

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved